Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease

NCT07599670 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07599670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07599670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 15, 2026
Completion date
October 31, 2030
Enrollment
210 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease